Market cap is the total market value to buy the whole company. It is equal to the share price times the number of Shares Outstanding (EOP). Eisai Co's share price for the quarter that ended in Dec. 2023 was 円7052. Eisai Co's Shares Outstanding (EOP) for the quarter that ended in Dec. 2023 was 287 Mil. Therefore, Eisai Co's market cap for the quarter that ended in Dec. 2023 was 円2,022,556 Mil.
Eisai Co's quarterly market cap
declined
from Jun. 2023 (円2,788,785 Mil) to Sep. 2023 (円2,381,537 Mil) and
declined
from Sep. 2023 (円2,381,537 Mil) to Dec. 2023 (円2,022,556 Mil).
Eisai Co's annual market cap
declined
from Mar. 2021 (円2,126,775 Mil) to Mar. 2022 (円1,625,612 Mil) but then
increased
from Mar. 2022 (円1,625,612 Mil) to Mar. 2023 (円2,152,102 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Eisai Co's Enterprise Value for Today is 円1,670,737 Mil.
Eisai Co Market Cap Historical Data
The historical data trend for Eisai Co's Market Cap can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Eisai Co's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Eisai Co's Market Cap Distribution in the Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Eisai Co's Market Cap distribution charts can be found below:
* The bar in red indicates where Eisai Co's Market Cap falls into.
Eisai Co Market Cap Calculation
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
Eisai Co's Market Cap for the fiscal year that ended in Mar. 2023 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Eisai Co (TSE:4523) Market Cap Explanation
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
Eisai Co Market Cap Related Terms
Thank you for viewing the detailed overview of Eisai Co's Market Cap provided by GuruFocus.com. Please click on the following links to see related term pages.
Eisai Co Ltd is a specialty and generic drug manufacturing company. The company's business consists of a pharmaceutical business and other businesses. The pharmaceutical business is categorized by region, including Japan, Americas, China, Asia, and Europe, Middle East, and Africa. Eisai also reports a consumer healthcare business for Japan. The vast majority of the company's revenue is derived by its Japanese pharmaceutical business, followed by its Americas pharmaceuticals segment. The company utilizes licensing strategies in order to expand its research, development, manufacturing, and marketing capabilities.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
TSE:4523 has been successfully added to your 